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NALOXONE THERAPY IN 
OPIOID OVERDOSE 
PATIENTS: INTRANASAL 
OR INTRAVENOUS?
A RANDOMIZED CLINICAL TRIAL
 There is an opioid crisis in the United States
 Naloxone is the drug of choice for reversing a suspected 
opioid overdose
 The intranasal route could be a viable option for the use of 
naloxone
 Intranasal could prove to be quicker with less skill needed to 
give while putting the healthcare workers, police, and 
firefighters at less risk of blood borne pathogen exposure 
OVERVIEW
 Opioid – a class of drug that interacts with the opioid receptors 
in the brain and body, often causing a euphoric state to the user
 Overdose – when too much of a drug is in a users system - can 
cause severe negative physiologic effects (coma, 
respiratory/cardiac arrest, death)
 Congener – a variant of a common chemical structure
 Antagonist – interferes with the physiological action of another 
substance 
 Receptors – a cell  that accepts and transmits a signal to sensory 
nerves
 Glasgow Coma Scale (GCS) – method for evaluating conscious 
level impairment
 Intravenous – administered through a vein
 Intranasal – administered through the nasal cavity 
 Intramuscular – administered in a muscle 
KEY TERMS
 In  2015,  33,000 people  
died from an opioid 
overdose
 Not just  i l legal  opioids 
are  responsible for  
deaths
 Methadone, oxycodone 
and hydrocodone are 
the most commonly 
abused prescription 
drugs 
 Heroin use is  on the r ise  
 One recommended 
act ion by the CDC is  to 
al low the use of  
naloxone to be 
expanded 1
OPIOID OVERDOSE EPIDEMIC
Chart of Overdose Deaths2
Molecular 
formula: 
C19H21NO4
Molecular 
weight:  
327.38 g/mol
CHEMICAL 
STRUCTURE 
OF 
NALOXONE3
 Naloxone is an opioid antagonist and is used for treatment of 
opioid overdose
 It is a competitive antagonist for the opioid (mu) receptors in the 
brain
 The mu receptors are where opioids bind themselves
 Naloxone displaces the opioid and attaches to the receptors, not 
allowing the opioid to reattach 
 The effects of Naloxone last for ~30-90 minutes (re-dosing may be 
required) allowing for the respiratory depression caused by the opioid 
to be suppressed 
 Naloxone is a very safe drug with no risk for dependency
 Routes for delivery include intranasal (IN), intravenous (IV), 
intramuscular (IM)4
WHAT IS NALOXONE 
HOW 
NALOXONE 
WORKS5
 Naloxone is a “synthetic congener of oxymorphone”
 The dif ference is an allyl group replaces the methyl group that 
is on the nitrogen atom6
Chemical  St ructure  Naloxone/Oxymorphone 7
MORE ABOUT NALOXONE
 Generally speaking, IV access can be difficult in IV 
drug users resulting in a delay in IV naloxone 
treatment
 Patients who have cardiovascular compromise also 
are difficult to obtain IV access
 There is a need for alternative delivery methods
 Other drugs have been proven effective when 
delivered IN route7
INTRODUCTION TO THE STUDY
 The trial was designed to compare the effects of IN vs IV 
administration
 They looked at 100 patients, ages 15-50, who had an opioid 
overdose
 There were 2 groups that were both given 0.4 mg naloxone either IV 
or IN
 Patient who failed to respond after the first dosing were re -dosed via 
the same route with another 0.4 mg
 Responses were gauged using the Glasgow coma scale (GCS) and 
level of consciousness (LOC), vital signs, arterial blood oxygen 
saturation, side-effects and how long they patient was hospitalized 
with LOC being the primary measure7
THE CLINICAL TRIAL
 There was not significant difference between the IN 
route and the IV route of administration
They were both effective 
 The IN route resulted in a better response with 
regards to LOC
 There was less agitation reported amongst the IN 
patients7
RESULTS OF THIS STUDY
 There are some discrepancies between this study 
and other studies of this type
Kerr et al. does not show there to be enough evidence 
to support first line IN dosing whereas this, and other 
studies, disagree
Merlin et al. reported no significant difference 
between IV or IN dosing
 Further studies need to be performed as this was a 
single institution and may not be representative of 
the population as a whole7
LIMITATIONS AND DISCREPANCIES 
 Thousands of people die every year related to the opioid 
overdose epidemic
 There is evidence that supports the use of IN naloxone 
administration 
 IV access is sometimes very dif ficult if not impossible in some 
patients
 IV access potentially puts healthcare workers at risk for blood 
borne pathogens
 It is possible to give IN naloxone without specialized training 
meaning that lay people could be able to give IN naloxone if 
needed
 More research needs to and should be done7
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